EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Empagliflozin to Prevent Progressive Adverse Remodelling After Myocardial Infarction (EMPRESS-MI): Rationale and Design

Jaclyn Carberry, Mark C Petrie, Matthew M Y Lee, Katriona Brooksbank, Ross T Campbell, Richard Good, Pardeep S Jhund, Peter Kellman, Ninian N Lang, Kenneth Mangion, Patrick B Mark, Alex McConnachie und 9 weitere

ESC Heart Failure · 2024

DOI: 10.1002/ehf2.14830 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ESC Heart Failure, 2024. Verfasst von Jaclyn Carberry und 20 weiteren Autor:innen. Beteiligte Einrichtung: British Heart Foundation Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow, UK. Hauptthemen laut MEDLINE: Benzhydryl Compounds, Glucosides, Magnetic Resonance Imaging, Cine, Myocardial Infarction. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Boehringer Ingelheim, British Heart Foundation Centre of Research Excellence Grant.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Patients with a reduced left ventricular ejection fraction (LVEF) following an acute myocardial infarction (MI) are at risk of progressive adverse cardiac remodelling that can lead to the development of heart failure and death. The early addition of a sodium-glucose cotransporter 2 (SGLT2) inhibitor to standard treatment may delay or prevent progressive adverse remodelling in these patients. Methods and results EMpagliflozin to PREvent worSening of left ventricular volumes and Systolic function after Myocardial Infarction (EMPRESS-MI) is a randomized, double-blind, placebo-controlled, multi-centre trial designed to assess the effect of empagliflozin on cardiac remodelling evaluated using cardiovascular magnetic resonance (CMR) in 100 patients with left ventricular systolic dysfunction following MI. Eligible patients were those ≥12 h and ≤14 days following acute MI, with an LVEF <45% by CMR. Patients were randomized to empagliflozin 10 mg once a day or matching placebo. The primary outcome will be change in left ventricular end-systolic volume indexed to body surface area over 24 weeks from randomization. Secondary endpoints include measures of left ventricular and atrial volumes, left ventricular mass, LVEF, and circulating cardiac biomarkers.

Conclusions

EMPRESS-MI will assess the effect of the SGLT2 inhibitor empagliflozin on cardiac remodelling in patients with left ventricular systolic dysfunction after an acute MI.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Benzhydryl CompoundsGlucosidesMagnetic Resonance Imaging, CineMyocardial InfarctionSodium-Glucose Transporter 2 InhibitorsVentricular Function, LeftVentricular RemodelingAgedFemaleHumansMaleMiddle AgedDisease ProgressionDouble-Blind MethodFollow-Up StudiesStroke VolumeMulticenter Studies as TopicRandomized Controlled Trials as Topic

Stichwörter der Autor:innen

Heart failureMyocardial infarctionSGLT2 inhibitor

Substanzen

Benzhydryl CompoundsempagliflozinGlucosidesSodium-Glucose Transporter 2 Inhibitors

Autor:innen und Institutionen

  • British Heart Foundation Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow, UK.
  • Golden Jubilee National Hospital, Clydebank, UK.
  • West of Scotland Innovation Hub, National Health Service, Glasgow, UK.
  • National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA.
  • Robertson Centre for Biostatistics, School of Health and Wellbeing, University of Glasgow, Glasgow, UK.

ORCID-Profile: Kieran F Docherty

Förderung

  • Boehringer Ingelheim
  • British Heart Foundation Centre of Research Excellence Grant

Zitieren

APA

Carberry, J., Petrie, M. C., Lee, M. M. Y., Brooksbank, K., Campbell, R. T., Good, R., Jhund, P. S., Kellman, P., Lang, N. N., Mangion, K., Mark, P. B., McConnachie, A., McMurray, J. J. V., Meyer, B., Orchard, V., Shaukat, A., Watkins, S., Welsh, P., Sattar, N., …, & Docherty, K. F. (2024). Empagliflozin to Prevent Progressive Adverse Remodelling After Myocardial Infarction (EMPRESS-MI): Rationale and Design. ESC Heart Failure. https://doi.org/10.1002/ehf2.14830

Vancouver

Carberry J, Petrie MC, Lee MMY, Brooksbank K, Campbell RT, Good R, et al. Empagliflozin to Prevent Progressive Adverse Remodelling After Myocardial Infarction (EMPRESS-MI): Rationale and Design. ESC Heart Failure. 2024. doi:10.1002/ehf2.14830

BibTeX
@article{Carberry2024,
  author = {Carberry, Jaclyn and Petrie, Mark C and Lee, Matthew M Y and Brooksbank, Katriona and Campbell, Ross T and Good, Richard and Jhund, Pardeep S and Kellman, Peter and Lang, Ninian N and Mangion, Kenneth and Mark, Patrick B and McConnachie, Alex and McMurray, John J V and Meyer, Barbara and Orchard, Vanessa and Shaukat, Aadil and Watkins, Stuart and Welsh, Paul and Sattar, Naveed and Berry, Colin and Docherty, Kieran F},
  title = {Empagliflozin to Prevent Progressive Adverse Remodelling After Myocardial Infarction (EMPRESS-MI): Rationale and Design},
  journal = {ESC Heart Failure},
  year = {2024},
  doi = {10.1002/ehf2.14830}
}
Kostenlos starten →